New Parkinson’s pathway maps out referral process for non-oral treatments

April 8th 2016 ...in category Commissioning Excellence

A new best practice pathway for the use of non-oral treatments in Parkinson’s has been devised by clinicians to make the referral process for these therapies more explicit.

The new guideline pathway, for the first time, gives clinicians a road-map for the use of non- oral therapy (apomorphine, intestinal levodopa gel infusion (Duodopa) and deep brain stimulation). For the right patients, these treatments can be truly life changing.

The tool will help clinicians understand referral criteria and the local process for referral. The framework can be tailored to suit any locality and has been developed with the guidance of a steering group of movement disorder specialists, clinicians from the UK Parkinson’s Excellence Network and neurological services commissioners.

Central to the pathway is ensuring clinicians know the referral routes for non-oral therapy and to make access fair across the country. It is not good enough that management of Parkinson’s is currently so variable, which means many patients who could benefit from non-oral treatments cannot access them.

Professor Ray Chaudhuri, Kings College Hospital, London, Clinical Director International Parkinson’s Centre of Excellence and Excellence Network Regional Lead for London (South), explained why non-oral therapies are so important in Parkinson’s:

“Non-oral therapies have been an under-appreciated therapeutic strategy for many years but now the issue has become important given some basic understanding of the extra cerebral pathology of Parkinson’s. We now know, as appreciated by James Parkinson himself, that the gut is dysfunctional in Parkinson’s right from the start of the motor disease. There is dysphagia and dribbling of saliva, right from the start of the motor disease in some patients. Continuing oral therapy here puts the patient at risk of aspiration pneumonia a common cause of morbidity in Parkinson’s. Then there is a major issue with delayed gastric absorption due to delayed emptying. This has now been clearly linked to phenomena such as early morning off, delayed on, and dose failures. Oral therapy in this situation may be ineffective. Add to this small intestinal bacterial overgrowth, constipation as well as bowel transit problems. Non oral therapies avoid this route and should form an essential part of the therapeutic strategy in Parkinson’s.

Dr Neil Archibald, Consultant Neurologist at James Cook University Hospital, Middlesbrough, Excellence Network Regional Lead for North East and Cumbria and steering group member, said:

“The publication of a detailed pathway for the use of non-oral therapies in Parkinson’s is overdue and incredibly helpful. For too long we’ve been using, or trying to use, these treatments in a rather haphazard fashion. Some patients, in some parts of the country seem to get access and some doctors, in some parts of the country, seem to be unaware of them! What we really need is a “best practice” tool to help inform the management of some of the more complex symptoms of Parkinson’s and now we have one.”

Most people with Parkinson’s however will not need this guideline - for many, tablet and patch medications manage their symptoms very well. Furthermore, not everyone who is struggling on tablet medications will benefit from non-oral treatments and, of those who try them, not all will tolerate them.

However, for those patients who find their oral treatments are not working well this new pathway means that in the future more patients will have the opportunity to have a discussion with a specialist about whether these treatments might have a role.

The non-oral treatment care pathway for Parkinson’s is an interactive PDF which enables clinicians to easily navigate specific elements of the pathway and access relevant documents, governance policy and further information all in one place, and can be downloaded here. The tool will be checked annually for updates (or if major changes occur to policy).

About the Author


Sue Thomas

Sue Thomas

Chief Executive for Commissioning Excellence

sue.thomas@nhis.com
View more posts by Sue Thomas

April 8th 2016
...in category Commissioning Excellence

Commissioning Excellence

As one of NHS England’s recognised niche specialist commissioning support providers, we offer a full range services to assist you in improving patient outcomes. Our experience covers all long term conditions, with a particular specialism in the field of neurology.

More Articles

...in category Commissioning Excellence

August 1st 2016

NHiS Commissioning Excellence appoints Associate Director for mental health support service

NHiS Commissioning Excellence appoints Associate Director for mental health support service

NHiS Commissioning Excellence, which helps the NHS and related patient organisations to plan and commission services, has appointed Laurence Mascarenhas as an Associate Director for its mental health support service.

July 12th 2016

New report finds technology investment is key to vanguards’ vision for the future of the NHS

New report finds technology investment is key to vanguards’ vision for the future of the NHS

The NHS must invest in new technology if innovative models of care being trialled by its vanguards are to be rolled out, according to a report by NHiS Commissioning Excellence, which helps the NHS plan and commission patient services.

April 29th 2016

Improving outcomes for people with MS

Improving outcomes for people with MS

This MS Awareness Week the MS Trust is highlighting the need for fair and equitable services for people with MS following their survey of 2000 people which shows there is a growing disparity in the care on offer.

Get in touch today to see how we can help


Call or email to tell us more about your challenges and we'll be sure to put you in touch with the right member of the NHiS team.

0845 121 3686

NHiS is a Wilmington Plc Company

www.wilmingtonplc.com


BSI and Ukas

IS 638885

ISO27001 Information Security Policy available on request

© NHiS Limited 2018. Registered Company Number: 05997573. Registered Address: 6-14 Underwood Street, London, N1 7JQ.